DEXCOM, INC.
About DEXCOM, INC.
DexCom, Inc. develops and commercializes continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers products including Dexcom G7, G6, ONE+, Stelo biosensor, Share remote monitoring, and Follow application. Its technology uses a small wearable sensor to measure glucose levels continuously and transmit readings to compatible receivers or smartphones.
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Publicly traded on NASDAQ: DXCM since 2005 IPO with $56.4M gross proceeds.
- Generated US$4.66 billion revenue in 2025 with US$836 million net income.
- Develops integrated CGM systems such as G7 and G6 used globally for diabetes management.
- Headquartered in San Diego with operations generating revenue in the US and internationally.
Ask StreetZero about DEXCOM, INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account